Menkes Disease (MD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Menkes Disease (MD) Market Outlook
Thelansis’s “Menkes Disease (MD)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Menkes Disease (MD) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Menkes
Disease (MD) Overview
Menkes
disease (MD) is a rare and grave multisystemic disorder characterized by
disruptions in copper metabolism. This condition, which primarily affects males
due to its X-linked recessive inheritance pattern, is associated with
progressive neurodegeneration, connective tissue abnormalities, and distinctive
‘kinky’ hair. The underlying cause of MD lies in mutations within the ATP7A
gene, with most of these mutations manifesting as intragenic alterations or
partial gene deletions. The ATP7A gene plays a crucial role as an
energy-dependent transmembrane protein responsible for transporting copper to
secreted copper enzymes while expelling excess copper from cells. This
intricate process ensures the delicate balance of copper within the body, and
any mutations in ATP7A can lead to the severe and life-threatening consequences
observed in Menkes disease. MD primarily affects males, with most patients
succumbing to the disease before reaching their third year of life. The
multisystemic impact of MD includes progressive neurodegeneration, resulting in
severe neurological symptoms. Additionally, connective tissue disturbances
contribute to the clinical manifestations of the disease. The peculiar ‘kinky’
hair is a distinctive external marker of Menkes disease.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment